Background Methionine inhibits proliferation of breast and prostate cancer cells. Here, we determined the inXuence of L-methionine on functional molecular signatures in these cell lines. Methods MCF-7 and LNCaP cells were treated with L-methionine (5 mg/ml) for 72 h. Changes in molecular signatures of these cells were examined by microarray analysis of 15,814 probes in triplicate experiments.
Introduction
Recent investigations using new research tools have pointed to the potential of peptides as future therapeutic agents. Peptides possess a variety of potential clinical beneWts, with applications in some of major categories of diseases, including cancer (Shrivastava et al. 2009; Vazquez et al. 2009 ). In addition to peptides, amino acid analogs are also potential candidates as new therapeutic agents. For example, our recent study (Benavides et al. 2007 ) has suggested that the amino acid methionine is a promising candidate anti-cancer compound, opening the prospect for development of methionine analogs as therapeutic agents.
Methionine is an essential amino acid that plays a key role in protein synthesis and in a number of other biochemical and cellular processes. Methionine is also implicated in DNA-methylation and protein-methylation by serving as the methyl-group donor, thereby serving an important role in regulation of gene expression and protein functions. Furthermore, methionine is required for the biosynthesis of the polyamines spermine and spermidine, which are critically involved in a number of cellular activities including cell proliferation (Thomas and Thomas 2001) .
One approach to identifying signiWcant molecular events of malignant transformation and tumor progression and to characterizing both known and suspected oncogenic pathways is to establish molecular signatures using gene expression proWling (Sweet-Cordero et al. 2005) . While such expression signatures of cancers are frequently confounded by the complexity of human tumors (Ji et al. 2003; Giustarini et al. 2004; Ji et al. 2004; Fagerholm et al. 2008) , they can be more informative when applied to in vitro systems and to genetically modiWed animal models where experimental variables can be controlled (Huang et al. 2003) .
We have previously shown that L-methionine possesses strong inhibitory eVects on cell proliferation in both breast and prostate cancer cell lines and is associated with posttranslational modiWcation of the tumor suppressor gene p53 (Benavides et al. 2007; Benavides et al. 2010) . In the present study, we have employed a global genomic approach to more comprehensively deWne gene signatures induced by L-methionine exposure of these cell lines and to understand the mechanisms that may underlie the methionine-mediated inhibitory eVects on cell survival and cell cycle progression.
Materials and methods

Cell lines and cell culture
Wild-type p53-expressing LNCaP prostate and MCF-7 breast cancer cells were obtained from the American Type Culture Collection (ATCC; Manassas, VA). MCF-7 cells were cultured in Minimum Essential Medium (MEM; Eagle; Invitrogen, Grand Island, NY) containing 2 mM L-glutamine (Mediatech-Cellgro, Manassas, VA) 1.5 mg/L sodium bicarbonate, 0.1 mM non-essential amino acids, and 1 mM sodium pyruvate supplemented with 10% fetal bovine serum (FBS; vol/vol) (HyClone Lab Inc.; Logan, UT) and 10 mg/mL insulin (Pratt and Pollak 1993; Takahashi and Suzuki 1993) . LNCaP (Horoszewicz et al. 1983 ) cells were cultured in RPMI 1640 media (Mediatech-Cellgro; Herndon, VA) supplemented with 10% FBS, 2 mM L-glutamine, antibiotic-antimycotic solution (1X; Mediatech-Cellgro), and MEM vitamin solution (1X; Mediatech-Cellgro). All cells were incubated at 37°C in a humidiWed atmosphere containing 5% CO 2 .
Experimental design
Cells were seeded in 6-well plates at a concentration of 100,000 cells per well in 2 ml of media. After 48 h, cells were given fresh media to which L-methionine had been added at a concentration of 5 mg/ml or control media without additional thionine. After 72 h, cells were harvested. Three independent experiments were carried out for this study.
RNA isolation and microarray analysis
Cells were washed three times with ice-cold PBS and harvested using a trypsin. Total RNA was extracted using the RNase Mini Kit (Qiagen, Valencia, CA) according to the manufacturer's instructions. The concentration and purity of total RNA were determined spectrophotometrically at 260 and 280 nm. The quality of the RNA preparation was further evaluated by agarose gel electrophoresis. Biotinlabeled cRNA was generated from high-quality total RNA using the Illumina TotalPrep RNA AmpliWcation kit (Ambion, Austin, TX). BrieXy, 350 ng of total RNA with high 260/280 absorbance ratio (>1.8) (Gallagher 2001) and RIN number was reverse-transcribed with an oligo primer bearing T7 promoter. The Wrst strands of cDNA, produced in the reaction, were used to make the second strands of cDNA. The puriWed second strands of cDNA along with biotin UTPs were used to generate biotinylated, antisense RNA of each mRNA in an in vitro transcription (IVT) reaction. The size distribution proWles for the labeled cRNA samples were evaluated by a bioanalyzer. PuriWed labeled cRNAs (1.5 g) were hybridized to the Sentrix Human-6 v2 Expression Beadchip by overnight incubation at 55°C. Signals were developed with Streptavidin-Cy3. The Illumina BeadArray Reader was used to scan the chips.
Microarray data analysis
The Illumina Human WG6 V3 Expression BeadChip (Illumina: San Diego, California) was used to measure genome-wide gene expression levels. For quality control and statistical power consideration, samples from each cell line and treatment were analyzed in triplicate. The samples from the same cell lines (LNCaP and MCF-7) were laid out on the same slide (6 samples/slide) to avoid possible batch eVects across slides. The Illumina Bead Array technology is based on randomly arranged beads, with each bead binding many (usually over 30) identical copies of a gene-speciWc probe. This redundant design yields high conWdence calls and robust estimations. To take advantage of this unique feature of Illumina BeadArray, we used the Bioconductor lumi package (Du et al. 2007; Dalle-Donne et al. 2009 ) to preprocess Illumina data with default settings. Basically, each array was Variance-Stabilizing Transforms (VST) transformed and then followed by quantile normalization across all samples (Lin et al. 2008) . Probes with intensity lower than or around background levels were Wltered.
A total of 15,814 probes were used for further analysis. To identify diVerentially expressed genes, routines implemented in Illumina Bioconductor package (Smyth 2004) to Wt linear models to the normalized expression values were applied. The variance used in the t-score calculation was corrected by an empirical Bayesian method (Smyth 2004) for better estimation relative to a small sample size. To control the eVects of multiple testing and reduce false positives, P-values were further adjusted based on False Discovery Rate (FDR) (Benjamini and Hochberg 1995) . We called genes with FDR-adjusted P-value <0.01 and a fold change >1.5 as diVerentially expressed genes.
Pathway analysis
Pathway Analysis was performed using Ingenuity Pathway Analysis (IPA 7.0) commercial software (www.Ingenuity.com). IPA information was extracted by Ingenuity from the scientiWc literature, including information about genes, drugs, chemicals, cellular and disease processes, and signaling and metabolic pathways. Expression data sets containing signiWcant diVerentially expressed gene identiWers (Entrez Gene identiWers) and their corresponding expression values as fold changes were uploaded as a tab-delimited text Wle. Each gene identiWer was mapped to its corresponding gene object in the Ingenuity Pathways Knowledge Base (IPKB). To start building networks, the application program queries the IPKB for interactions between focus genes and all other gene objects stored in the knowledge base and generates a set of networks. The program then computes a score for each network according to the Wt of the network to the set of focus genes. The score indicates the likelihood of the focus genes in a given network being found together due to random chance. A score of larger than 2 indicates that there is a less than 1 in 100 chance that the focus genes were assembled randomly into a network due to random chance.
Quantitative reverse transcription-PCR (QRT-PCR)
Reverse transcription was carried out with a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA) on the total RNA isolated from LNCaP and MCF-7 cells that had been cultured for 72 h with or without L-methionine (5 mg/ml) using the RNeasy kit from Qiagen. PCR conditions and sequence for each primer are shown in Table 1 . PCR products were separated on a 1% agarose gel. Expression of a housekeeping gene, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), was used to normalize the PCR. For real-time PCR, cDNA was mixed with primers and SYBR Green PCR Master Mix according to the manufacturer's instructions (Applied Biosystems). Real-time PCR was carried out by an ABI7900-HT sequence detection system from Applied Biosystems for relative quantitation of mRNA levels, and the mRNA levels in methionine-exposed cells were plotted as fold increase compared with untreated samples. GAPDH was used for normalization C t values (target gene C t minus GAPDH C t ) for each triplicate sample was averaged. C t was calculated as previously described, and mRNA ampliWcation was determined by the formula 2 ¡ C t . For the real-time PCR of AKR1C2, we used the Taqman Gene Expression Assay from Applied Biosystems; the AKR1C2 Assay ID was Hs00912742_m1, and the GAPDH the assay ID was Hs99999905_m1.
Results
In this study, we compared the eVects of treatment for 72 h with L-methionine at 5 mg/ml on gene expression in LNCaP prostate cancer cells and MCF-7 breast cancer cells, using as criteria a false discovery rate (FDR) P-value of greater than 0.01 and a change in expression of greater than 1.5-fold to select genes of interest in three independent experiments. Heatmaps were created to visualize the overall expression patterns of genes diVerentially expressed in LNCaP and MCF-7 cells treated with methionine or media without methionine added; the expression proWle detected by each probe was Wrst standardized with zero mean and one standard deviation. Clear diVerences in expression patterns were observed between LNCaP cells treated L-methionine and LNCaP controls and, to a lesser extent, between MCF-7 cells treated with methionine and MCF-7 cells given media without methionine added (Fig. 1) .
The expression patterns of the majority of these genes were changed by methionine in the same direction in both cells lines. Volcano plots were created to indicate the strength of biological eVects (fold change) versus the reproducibility of the result (P-value); each gene is represented as a dot in these plots (Fig. 2) . Treatment with L-methionine Tables 1 and 2 ). To explore the functional relevance of these Wndings and the observed commonalities and diVerences between the breast and prostate cancer cell lines, we Wrst used Venn diagrams to identify overlapping gene signature responses to methionine between LNCaP and MCF-7 cells, again using the same criteria: FDR-adjusted P-value of <0.01 and a fold change of >1.5. This analysis revealed that 98 genes were modiWed by L-methionine treatment in the same direction in both cell lines, of which 10 genes were up-regulated and 88 genes were down-regulated (Table 2 and Fig. 3 ). In addition, the expression of the following Wve other genes was changed in opposite directions by L-methionine in LNCaP and MCF-7 cells (Fig. 3) . H1 histone family member 0 (H1F0), Centromere Protein N (CENPN), and AcetylCoenzyme A Acetyltransferase 2 were up-regulated in LNCaP cells by 1.99 (P < 0.001), 1.65 (P < 0.00005), and 1.55-fold (P < 0.00001), respectively. In MCF-7 cells, these genes were down-regulated by 1.66 (P < 0.0005), 1.59 (P < 0.0005), and 1.57-fold (P < 0.002), respectively. In addition, Tumor Necrosis Factor Super Family member 2 (TNF-2) and Dehydrogenase/Reductase member 2 (DHRS2) were down-regulated in LNCaP by 1.75 and ¡1.52-fold, respectively (P < 0.0005), but they were upregulated were up-regulated in MCF-7 cells by 1.51 (P < 0.0005), and 1.55-fold (P < 0.001), respectively. There was more variation in the response of MCF-7 cells to methionine in repeat experiments than for LNCaP cells (Fig. 3) , which we cannot explain.
The 98 genes whose expression was modiWed by L-methionine treatment in the same direction in both cell lines were then analyzed using the data-mining tool IPA 7.0 (www.Ingenuity.com). Using this tool, we searched for functional relationships between diVerentially expressed genes identiWed in these microarray studies and those genes annotated in the Ingenuity knowledge base, the largest manually gene annotation database based on functional information available in published studies (www.Ingenuity. com). Six networks were identiWed that were deWned as groups of two or more genes that are linked by a functional association, based on peer-reviewed published data.
Of these six functional network groups (summarized in Table 3 ), in group 1 (cancer, cell cycle and reproductive system diseases), only the LAMA3 gene was up-regulated, whereas 86% of genes were down-regulated and 11% was unchanged in their expression. In group 2 (cell cycle, cell assembly/organization, DNA replication, recombination and repair), only GPX8 was up-regulated, while 57% of genes were down-regulated and 40% remained unchanged. In group 3 (DNA replication, recombination and repair, cancer, and gastrointestinal disease), two genes (NQO1 and C8ORF4) were up-regulated. Fifty-one percent of the remaining genes were down-regulated, and 43% genes were unchanged. In group 4 (cancer, gastrointestinal disease and cell cycle), two genes (ATF3 and SH3BGRL) were up-regulated. In this group, 46% of genes were downregulated, and 49% genes were unchanged. In group 5 (cancer, gastrointestinal disease, genetic disorders), four genes (AFF3, AKR1C2, RBM4B, and VAMP5) were up-regulated. Thirty-four percent of genes in this group were down-regulated, and 54% genes were unchanged. Of the two genes in group 6 (cell death, neurological diseases, nervous system development and function), the FBXO38 gene was down-regulated, and KLF7 was unchanged.
To conWrm the expression of key genes diVerentially regulated by the L-methionine treatment, the expression of the ten genes that were up-regulated (e.g., AFF3, AKR1C2, ATF3, C8ORF4, GPX8, LAMA3, RBM4B, NQO1, SH3BGRL, and VAMP5) was further assessed by real-time RT-PCR analysis, and their expression was compared with the changes in expression patterns detected by the microarray analysis. There was strong induction of the mRNA expression of each of these genes after treatment with L-methionine using both microarray analysis and real-time RT-PCR (Table 1) .
Discussion
In the present study, we identiWed, using microarray analysis, 98 genes whose expression was increased (10 genes) or decreased (88 genes) by treatment with L-methionine for 72 h at the non-apoptosis-inducing concentration of 5 mg/ ml in both prostate cancer LNCaP cells and breast cancer MCF-7 cells. The expression of Wve genes was modiWed in opposite directions in these two cell lines. The dysregulation of these 98 genes in both breast and prostate cancer cells suggests that the aVected genes are potential common regulatory targets of methionine and, possibly, methionine analogs. On the other hand, there were considerable diVerences between these two cell lines in the eVect of methionine. L-methionine caused signiWcant expression changes of 842 genes in LNCaP cells, whereas only 221 genes were aVected in MCF-7 cells. It is not clear why this diVerence occurred, but of note, MCF-7 cells are also less sensitive to inhibition of cell proliferation caused by methionine (Benavides et al. 2010) . Three of the genes up-regulated by L-methionine in both cell lines, NAD (P)H:quinone oxidoreductase (NQO1), SH3BGRL (SH3BGRL), and glutathione peroxidase 8 (GPX8), are associated with changes in cellular thiol redox balance and are involved cellular defense against oxidative stress (ForthoVer et al. 2002; Mazzocco et al. 2002; SantaCruz et al. 2004; Toppo et al. 2008; Yin et al. 2005) . These Wndings suggests that L-methionine may induce antioxidant eVects and consequently regulate the cellular pool of glutathione, which is required for maintaining the reduced state of cellular protein thiol groups (Metayer et al. 2008) . It is conceivable that the induction of these antioxidant-related genes by L-methionine may bring about increased antioxidant capacity in cancer cells. Of note, methionine also serves as a precursor of glutathione, a tripeptide that is a regulator of intracellular redox homeostasis, which by reducing a sulfhydryl-containing reactive oxygen species (ROS) safeguards cells from oxidative stress (Anderson 1998) . NQO1 serves as a quinone reductase in connection with conjugation reactions of hydroquinones involved in detoxiWcation pathways in addition to other functions (Bello et al. 2001) . Reduced expression of NQO1 has been detected in breast cancer cells and is believed to be a strong prognostic and predictive factor in breast cancer (Fagerholm et al. 2008) . SH3BGR has been suggested to represent a novel class of thioredoxin fold proteins belonging to the thioredoxin superfamily (Yin et al. 2005) . GPX8 reduces hydrogen peroxide by transferring the energy of the reactive peroxides to a glutathione (Toppo et al. 2008) .
Interestingly, also up-regulated was aldo-keto reductase family 1, member C2 (AKR1C2), which catalyzes the inactivation of the potent androgen 5-alpha-dihydrotestosterone (5-alpha-DHT) to 5-alpha-androstane-3-alpha, 17-beta-diol (3-alpha-diol), thereby possibly reducing androgen activity in LNCaP cells (Lou et al. 2006) . The expression of AKR1C2 is known to be reduced in both prostate cancer and breast cancer cells (Ji et al. 2003 (Ji et al. , 2004 . Fig. 3 Heatmap of genes the expression of which was altered by L-methionine treatment in both LNCaP and MCF-7 cells, comparing methionine-treated (Pos) and untreated control (Neg) cells in three independent experiments (1, 2, and 3). Of these 103 genes, 98 were regulated in the same direction by this treatment, with 10 genes up-regulated and 88 genes down-regulated in both cancer cell lines. The expression of Wve other genes was changed in opposite directions in the two cell lines (see text of results) Table 3 Classes of L-methionine-responsive gene signatures and their top functions
The genes were classiWed based on molecular networks (www.Ingenuity.com; see text). The downward arrows indicate genes that were down-regulated by L-methionine exposure in both LNCaP and MCF-7 cells, and the upward arrows indicate genes that were up-regulated in both cell lines. The expression of genes indicated without arrows and not in bold-face in these networks was unchanged in response to L-methionine treatment; the expression of four of these genes was changed in only one of the two cell lines (NCAPD3, UBE2A, ADAM15, and C4ORF43). Ingenuity Pathways Analysis computes a score for each network according to the Wt of that network to the user-deWned set of Focus Genes. This score is derived from a P-value and indicates the likelihood of the Focus Genes in a particular network being found together due to random chance. A score of 2 indicates that there is a 1 in 100 chance that the Focus Genes are together in a network due to random chance. Therefore, scores of 2 or higher have at least a 99% conWdence of not being generated by random chance alone. This score is given in the third column of this A large number of genes that were down-regulated by L-methionine are members of protein kinase families. It is likely that many of these genes are associated with control of cell proliferation. Pathway analysis indicated down-regulation of a large number of genes involved in cancer, cell cycle, cell assembly and/or involved in organization, cell replication, recombination/repair of DNA, gastrointestinal disease, and genetic disorders by Lmethionine treatment. This could be consistent with the inhibitory eVects of L-methionine on LNCaP and MCF-7 cell growth (Benavides et al. 2007; Benavides et al. 2010) . On the other hand, no eVects in gene groups associated with methionine metabolism speciWcally were detected by pathway analysis. Nevertheless, the array data generated in this study form the basis of future studies with multiple methionine doses and time points comparing not only breast and prostate cancer cells, but also cancer cells with non-tumorigenic cells from the same tissues. This is particularly important in view of the fact that methionine only inhibits cell cycle progression in breast and prostate cancer cells but not in non-tumorigenic breast and prostate epithelial cells (Benavides et al. 2010 ). Although such future hypothesis generating studies would also provide suYcient data to develop and test models that explore how methionine may selectively aVect cancer cells, they should also focus on generating experimental evidence that the observed changes in expression of the genes have functional signiWcance. For example, the potential modifying eVects of methionine on antioxidant mechanisms would be one fruitful area of future investigation.
In summary, this study indicates that L-methionine induces common changes in molecular signatures of MCF-7 breast cancer cells and LNCaP prostate cancer cells, down-regulating genes belonging to protein kinase families, which may be related to the anti-proliferative eVects of this amino acid on these cells. L-methionine also up-regulated some genes involved in cellular redox regulation suggesting antioxidant activity-enhancing properties of this amino acid. Future studies of the mechanisms and consequences of cellular and molecular eVects of L-methionine and development of methionine analogs that lack the potential negative eVects of methionine itself on the well-known methionine-dependence of many tumor cells (Judde et al. 1989 ) may eventually lead to exploitation of analogs of this amino acid in cancer therapy.
